Eli Lilly's Tirzepatide Sales in 2024 and What They Mean for Access in the UK

You saw the headline: tirzepatide just had one of pharma's biggest years. Here's why that happened.

Picture this: you're scrolling the financial news in early 2025 and a headline tells you a weight-loss drug just made Eli Lilly the most valuable pharmaceutical company in Europe. That drug is tirzepatide. The question most people ask next is a reasonable one: if it sold that much, why was it so hard to get hold of?

The short answer is that demand arrived faster than any manufacturer's supply chain could absorb. In the United States, tirzepatide launched under the brand Ozempic's shadow but quickly outpaced it on clinical data. In the UK, the Lilly tirzepatide story played out differently: the medicine received its UK weight-management licence in 2023, NICE recommended it in December 2024 under technology appraisal TA1026, and a price increase from Eli Lilly followed on 1 September 2025 once demand had crystallised. The 2024 sales figures reflect the period just before that price shift, when private supply was expanding rapidly but NHS access was still largely theoretical for most patients.

One misconception worth clearing up gently: high sales don't mean the medicine has become easier to obtain without a clinical assessment. Mounjaro remains a prescription-only medicine regardless of how many units Lilly ships. The volume of legitimate prescriptions written is the metric that actually matters for patients, and that number grew substantially throughout 2024 as more private providers entered the market and GP prescribing pathways began to be established.

What Eli Lilly's 2024 tirzepatide revenues tell us about supply and UK pricing today

Lilly reported tirzepatide revenues of roughly $5.2 billion for the full year 2024, driven primarily by the United States, where both the weight-management brand (Zepbound, US only) and the diabetes brand (Mounjaro) were selling simultaneously. The UK knows only the Mounjaro name; Zepbound is the US brand and does not exist as a UK product.

For UK pricing context, the 2024 sales period preceded a significant shift. From 1 September 2025, Eli Lilly raised Mounjaro's UK list price substantially, with the highest-dose pen rising from around £122 to around £330, as widely reported at the time. That change is documented on our Eli Lilly Mounjaro UK price increase page for anyone who wants the detail. What the 2024 numbers show is that demand was already robust at the lower list price, which partly explains why Lilly felt confident making the adjustment.

It is also worth noting that commercial success funds production capacity. Lilly invested billions in new manufacturing facilities through 2024 and 2025 specifically to address tirzepatide shortages. The supply situation in the UK has improved markedly compared with the scarcity seen in the first half of 2024, when patients on some dose steps faced genuine waits. That trajectory matters practically: patients starting treatment today are less likely to encounter the mid-treatment gaps that made 2024 frustrating for some.

For a broader look at how tirzepatide sales figures have evolved across the UK and global markets, that page gives the fuller picture. If you're weighing up the medicine itself, our tirzepatide overview is the cleaner starting point.

NICE TA1026, NHS rollout, and what commercial demand actually changed for patients

NICE's December 2024 recommendation arrived during tirzepatide's highest-profile commercial period, and that timing was not coincidental. The volume of real-world prescribing data, supply-chain evidence, and manufacturer engagement that underpins a NICE submission is closely tied to how seriously a medicine is being taken commercially. By the time the TA1026 committee met, tirzepatide had a substantial body of evidence and a manufacturer investing heavily in UK infrastructure.

What TA1026 actually recommends is specific: tirzepatide for NHS use in adults with a BMI of 35 or above plus at least one weight-related condition, with thresholds 2.5 kg/m² lower for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. The NHS rollout is phased, and access through a GP is still limited depending on where you live and which cohort you fall into. Our page on Eli Lilly's Mounjaro covers the distinction between the NHS route and private prescribing in more detail.

Private prescribing through a registered pharmacy remains the practical route for most people who want to start now. A prescriber still reviews every case individually: the commercial popularity of the medicine has no bearing on whether it suits a particular person's health profile. The NHS's tirzepatide information page sets out the standard eligibility framework and side-effect profile clearly if you want to read the clinical picture before taking any further steps.

Our clinical team reviews every consultation at nume personally; if you'd like to understand whether tirzepatide might be appropriate for you, that's the right place to begin. Speak to our prescribers through a free consultation and get a same-day clinical review.